A phase I/II open-label, dose-escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide (Revlimid) with topotecan in subjects with advanced ovarian and primary peritoneal carcinoma

Trial Profile

A phase I/II open-label, dose-escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide (Revlimid) with topotecan in subjects with advanced ovarian and primary peritoneal carcinoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2006

At a glance

  • Drugs Lenalidomide; Topotecan
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top